Global Nucleic Acid Amplification Testing Market Growth, Size, Trends Analysis- By Type, By Application, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Global Nucleic Acid Amplification Testing Market Introduction and Overview

According to SPER market research, 'Global Nucleic Acid Amplification Testing Market Size- By Type, By Application, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Nucleic Acid Amplification Testing Market is predicted to reach 37.78 Billion by 2034 with a CAGR 12.46%.

Nucleic Acid Amplification Testing (NAAT) is a powerful diagnostic technique that identifies the presence of specific genetic material (DNA or RNA) from pathogens like viruses, bacteria, or even human cells associated with genetic disorders. The core principle of NAAT involves taking a tiny amount of this genetic material from a patient's sample (such as blood, saliva, or a swab) and then creating millions or billions of copies of it.

Restraints: The Nucleic Acid Amplification Testing (NAAT) market faces some significant hurdles that could slow its expansion. One big issue is the high cost and complexity of the equipment needed, like the thermal cyclers used for PCR tests. This makes it tough to use NAATs in places with limited resources or at point-of-care locations.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Type, By Application, By End Use

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Danaher Corporation, Abbott Laboratories, Illumina, Inc., Siemens Healthineers, bioMA(C)rieux SA, Novartis AG, Bio-Rad Laboratories, Inc., Seegene Inc.

Global Nucleic Acid Amplification Testing Market Segmentation:

By Type: Based on the Type, Global Nucleic Acid Amplification Testing Market is segmented as; Polymerase Chain Reaction (PCR) Tests, Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, Ligase Chain Reaction (LCR) Tests.

By Application: Based on the Application,, Global Nucleic Acid Amplification Testing Market is segmented as; Infectious Disease Testing, Oncology Testing, Genetic & Mitochondrial Disease Testing, Others.

By End-use: Based on the End-use, Global Nucleic Acid Amplification Testing Market is segmented as; Hospitals, Central And Reference Laboratories, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Product Code: HLCA25168

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTERs Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Global Nucleic Acid Amplification Testing Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Nucleic Acid Amplification Testing Market

7.Global Nucleic Acid Amplification Testing Market, By Type, (USD Million) 2021-2034

7.1.Polymerase Chain Reaction (PCR) Tests
7.2.Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
7.3.Ligase Chain Reaction (LCR) Tests

8.Global Nucleic Acid Amplification Testing Market, By Application, (USD Million) 2021-2034

8.1.Infectious Disease Testing
- 8.1.1.COVID-19 Testing
- 8.1.2.Mosquito Borne Disease Testing
- 8.1.3.Influenza Testing
- 8.1.4.Sexually Transmitted Infections Testing
- 8.1.5.Hepatitis Testing
- 8.1.6.Tuberculosis Testing
- 8.1.7.Others
8.2.Oncology Testing
8.3.Genetic & Mitochondrial Disease Testing
8.4.Others

9.Global Nucleic Acid Amplification Testing Market, By End-use, (USD Million) 2021-2034

9.1.Hospitals
9.2.Central And Reference Laboratories
9.3.Others

10.Global Nucleic Acid Amplification Testing Market, (USD Million) 2021-2034

10.1.Global Nucleic Acid Amplification Testing Market Size and Market Share

11.Global Nucleic Acid Amplification Testing Market, By Region, 2021-2034 (USD Million)

11.1.Asia-Pacific
- 11.1.1.Australia
- 11.1.2.China
- 11.1.3.India
- 11.1.4.Japan
- 11.1.5.South Korea
- 11.1.6.Rest of Asia-Pacific
11.2.Europe
- 11.2.1.France
- 11.2.2.Germany
- 11.2.3.Italy
- 11.2.4.Spain
- 11.2.5.United Kingdom
- 11.2.6.Rest of Europe
11.3.Middle East and Africa
- 11.3.1.Kingdom of Saudi Arabia
- 11.3.2.United Arab Emirates
- 11.3.3.Qatar
- 11.3.4.South Africa
- 11.3.5.Egypt
- 11.3.6.Morocco
- 11.3.7.Nigeria
- 11.3.8.Rest of Middle-East and Africa
11.4.North America
- 11.4.1.Canada
- 11.4.2.Mexico
- 11.4.3.United States
11.5.Latin America
- 11.5.1.Argentina
- 11.5.2.Brazil
- 11.5.3.Rest of Latin America

12.Company Profile

12.1.F. Hoffmann-La Roche Ltd
- 12.1.1.Company details
- 12.1.2.Financial outlook
- 12.1.3.Product summary
- 12.1.4.Recent developments
12.2.Becton, Dickinson and Company
- 12.2.1.Company details
- 12.2.2.Financial outlook
- 12.2.3.Product summary
- 12.2.4.Recent developments
12.3.Danaher Corporation
- 12.3.1.Company details
- 12.3.2.Financial outlook
- 12.3.3.Product summary
- 12.3.4.Recent developments
12.4.Abbott Laboratories
- 12.4.1.Company details
- 12.4.2.Financial outlook
- 12.4.3.Product summary
- 12.4.4.Recent developments
12.5.Illumina, Inc
- 12.5.1.Company details
- 12.5.2.Financial outlook
- 12.5.3.Product summary
- 12.5.4.Recent developments
12.6.Siemens Healthineers
- 12.6.1.Company details
- 12.6.2.Financial outlook
- 12.6.3.Product summary
- 12.6.4.Recent developments
12.7.bioMA(C)rieux SA
- 12.7.1.Company details
- 12.7.2.Financial outlook
- 12.7.3.Product summary
- 12.7.4.Recent developments
12.8.Novartis AG
- 12.8.1.Company details
- 12.8.2.Financial outlook
- 12.8.3.Product summary
- 12.8.4.Recent developments
12.9.Bio-Rad Laboratories, Inc.
- 12.9.1.Company details
- 12.9.2.Financial outlook
- 12.9.3.Product summary
- 12.9.4.Recent developments
12.10.Seegene Inc.
- 12.10.1.Company details
- 12.10.2.Financial outlook
- 12.10.3.Product summary
- 12.10.4.Recent developments
12.11.Others